Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharmaceuticals Regulatory News (FARN)

Share Price Information for Faron Pharmaceuticals (FARN)

Share Price is delayed by 15 minutes
Get Live Data
43.50    0.00 (0.00%)
Bid:
42.00
Ask:
45.00
Spread: 3.00 (7.143%)
Market Cap: £88.25m
FARN Live PriceLast checked at - London Stock Exchange

Intraday Faron Pharmaceuticals Share Chart

Holdings in Company

30 May 2017 14:06

RNS Number : 5889G
Faron Pharmaceuticals Oy
30 May 2017
 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Faron Pharmaceuticals Oy

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

City Financial Investment Company Limited, acting as Investment Manager and Authorised Corporate Director of the City Financial Absolute Equity Fund

 

4. Full name of shareholder(s)  (if different from 3.):iv

BNY Mellon Trust and Depositary as Trustee to the City Financial Absolute Equity Fund

 

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

26 May 2017

6. Date on which issuer notified:

30 May 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

4%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

1,105,530

1,140,530

1,140,530

1,105,530

1,105,530

0

3.98%

0

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

1,105,530

3.98%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

The voting rights are managed and controlled by City Financial Investment Company Limited, Investment manager and ACD to the City Financial Absolute Equity Fund.

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

Ben Ellenbogen

15. Contact telephone number:

0207 451 9600

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLXBLFXDEFBBBZ
Date   Source Headline
11th Jun 20263:05 pmMFNFaron Pharmaceuticals: FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
11th Jun 20263:00 pmMFNFaron Pharmaceuticals: Faron Pharmaceuticals Ltd: Registration of Treasury Shares
10th Jun 20265:45 pmMFNFaron Pharmaceuticals: FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
8th Jun 20265:30 pmMFNFaron Pharmaceuticals: FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
5th Jun 202611:50 amMFNFaron Pharmaceuticals: Faron Pharmaceuticals Receives Decision from Nasdaq Helsinki Disciplinary Committee
4th Jun 20261:00 pmMFNFaron Pharmaceuticals: FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
3rd Jun 202612:00 pmMFNFaron Pharmaceuticals: Faron Pharmaceuticals Ltd: Registration of New Shares
3rd Jun 20267:00 amMFNFaron Pharmaceuticals: Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds
1st Jun 20261:00 pmMFNFaron Pharmaceuticals: FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
28th May 20262:00 pmMFNFaron Pharmaceuticals: FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
28th May 20261:35 pmMFNFaron Pharmaceuticals: Faron Pharmaceuticals Ltd: Issue of Treasury Shares to the Company
28th May 20261:30 pmMFNFaron Pharmaceuticals: Faron Pharmaceuticals Ltd: Special Rights attached to the First and Second Tranche of Bonds
18th May 20267:00 amMFNFaron Pharmaceuticals: FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
6th May 20266:00 amMFNFaron Pharmaceuticals: Faron Pharmaceuticals Ltd: Termination of Liquidity Provision Service
5th May 20267:30 amMFNFaron Pharmaceuticals: FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
5th May 20266:00 amMFNFaron Pharmaceuticals: Faron Pharmaceuticals Ltd: Directorate Appointment
4th May 202611:00 amMFNFaron Pharmaceuticals: Faron Pharmaceuticals Ltd: Results of the Annual General Meeting
30th Apr 20266:00 amMFNFaron Pharmaceuticals: Faron Pharmaceuticals Ltd: Issuance of warrants
22nd Apr 202611:30 amMFNFaron Pharmaceuticals: FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
20th Apr 20267:15 amMFNFARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
20th Apr 20267:00 amMFNFARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
16th Apr 20263:00 pmMFNFARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
14th Apr 202612:15 pmMFNFaron Pharmaceuticals Ltd: Remaining offer shares registered with Finnish Trade Register
14th Apr 20267:45 amMFNFaron Pharmaceuticals Ltd: Registration of New Shares
13th Apr 202611:00 amMFNFaron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds
10th Apr 20261:30 pmMFNNOTICE OF FARON PHARMACEUTICALS LTD’S ANNUAL GENERAL MEETING
10th Apr 202612:55 pmMFNFaron Pharmaceuticals Ltd: New shares registered with Finnish Trade Register
9th Apr 20265:25 pmMFNFaron publishes final results of its EUR 40.1 million rights issue
8th Apr 20262:15 pmMFNInside Information: Faron publishes preliminary results of its successful rights issue
31st Mar 20266:00 amMFNFaron Pharmaceuticals Ltd: Director Dealing
30th Mar 20267:30 amRNSSuspension - Faron Pharmaceuticals Oy
26th Mar 20267:00 amMFNFaron Pharmaceuticals Ltd: Faron appoints new CTO to strengthen late-stage development activities
25th Mar 20268:00 amMFNFaron Pharmaceuticals Ltd: Director Dealing
24th Mar 20264:30 pmMFNFARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
19th Mar 20267:10 amMFNFaron Pharmaceuticals Ltd: Director Dealing
19th Mar 20267:05 amMFNFaron Pharmaceuticals Ltd: Director Dealing
19th Mar 20267:00 amMFNFaron Pharmaceuticals Ltd: Director Dealing
12th Mar 20262:30 pmRNSFARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
12th Mar 20262:30 pmMFNFARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
11th Mar 20266:20 pmRNSThe Finnish Financial Supervisory Authority has approved Faron's rights offering prospectus
11th Mar 20266:20 pmMFNThe Finnish Financial Supervisory Authority has approved Faron's rights offering prospectus
11th Mar 20268:00 amRNSFARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
10th Mar 20267:48 amRNSInside Information: Faron publishes the terms and conditions of a fully covered rights offering of approximately EUR 40 million and updates cash runway
10th Mar 20267:48 amMFNInside Information: Faron publishes the terms and conditions of a fully covered rights offering of approximately EUR 40 million and updates cash runway
9th Mar 20265:45 pmMFNUpdate to Faron's Financial Calendar and date of the Annual General Meeting in 2026
4th Mar 20264:45 pmMFNCorrection: Faron Pharmaceuticals Ltd's Annual Report 2025 published
4th Mar 20267:15 amMFNFaron Pharmaceuticals Ltd's Annual Report 2025 published
4th Mar 20267:00 amMFNFaron's Financial Statements Release 1 January to 31 December 2025
2nd Mar 202610:00 amMFNFaron Pharmaceuticals Ltd: Results of the Extraordinary General Meeting
9th Feb 20265:45 pmMFNFaron Pharmaceuticals Ltd: NOTICE TO THE EXTRAORDINARY GENERAL MEETING

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.